Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

The effect of hydralazine on steady-state plasma concentrations of metoprolol in pregnant hypertensive women

  • 49 Accesses

  • 3 Citations

Summary

We have studied the plasma concentrations levels of metoprolol after its twice daily administration in a dose of 50 mg for 4 days in ten, hypertensive pregnant women to the during monotherapy and in combination with 25 mg of hydralazine given twice daily.

Hydralazine increased the median AUC and Cmax of metoprolol by 38% and 88% respectively, and decreased the tmax from 1.5 h to 1.0 h.

Hydralazine had no effect on the plasma concentrations of alpha-OH-metoprolol.

These results suggest that the effect of hydralazine on metoprolol plasma concentrations is primarily due to a reduction in first-pass elimination.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Sandström B (1982) Adrenergic beta-receptor blockers in hypertension of pregnancy. Clin Exp Hypertens [B] 1: 127–141

  2. 2.

    Lindberg B, Sandström B (1981) How Swedish obstetricians manage hypertension in pregnancy. Acta Obstet Gynecol Scand 60: 327–331

  3. 3.

    Benfield P, Clissold SP, Brogden RN (1967) Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficiency in hypertension, ischemic heart disease and related cardiovascular disorders. Drugs 31: 369–461

  4. 4.

    Regårdh CG, Borg KO, Johansson R, Johnsson G, Palmer L (1974) Pharmacokinetic studies on the selective β1-receptor antagonist metoprolol in man. J Pharmacokinet Biopharm 2: 347–364

  5. 5.

    Borg KO, Carlsson E, Hoffmann K-J, Jönsson T-E, Thorin H, Wallin B (1975) Metabolism of metoprolol-(3H) in man, the dog and the rat. Acta Pharmacol Toxicol 36: [Suppl 5]: 125–135

  6. 6.

    Regårdh CG, Ek L, Hoffmann K-J (1979) Plasma levels and β-blocking effect of α-hydroxy-metoprolol — metabolite of metoprolol — in the dog. J Pharmacokinet Biopharm 7: 471–479

  7. 7.

    Högstedt S, Lindberg B, Peng DR, Regårdh CG, Rane A (1985) Pregnancy-induced increase in metoprolol metabolism. Clin Pharmacol Ther 37: 688–692

  8. 8.

    Högstedt S, Rane A (1986) Plasma concentration-effect relationship of metoprolol during and after pregnancy. In: Högstedt S (ed) Hypertension in pregnancy an epidemiological, clinical and experimental study with special reference to metoprolol treatment. Acta Universitatis Upsaliensis, Dis 27

  9. 9.

    McLean AJ, Skews H, Bobic A, Dudley DJ (1980) Interaction between oral propranolol and hydralazine. Clin Pharmacol Ther 27: 726–732

  10. 10.

    Jack D, Kendall MJ, Dean S, Laugher SJ, Zaman R (1982) The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: Metoprolol, nadolol, and acebutolol. Biopharm Drug Dispos 3: 47–54

  11. 11.

    Byrne AJ, McNeil JJ, Harrison PM, Louis W, Tonkin AM, McLean AJ (1984) Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: Evidence implicating substrate delivery rate as a determinant of presystemic drug interactions. Br J Clin Pharmacol 17: 45S-50S

  12. 12.

    Ervik M, Hoffmann K-J, Kyhlberg-Hanssen K (1981) Selected ion monitoring of metoprolol and two metabolites in plasma and urine using deuterated internal standards. Biomed Mass Spectrom 8: 323–326

  13. 13.

    Schneck D, Varg JE (1983) Mechanism by which hydralazine alters the bioavailability of propranolol. Clin Pharmacol Ther 33: 261 (abstract)

  14. 14.

    Melander A, McLean AJ (1983) Influence of food intake on presystemic clearance of drugs. Clin Pharmacokinet 8: 286–296

  15. 15.

    McLean AJ, McNamara PJ, du Souich P, Gibaldi M, Lalka D (1978) Food, splanchnic blood flow and bioavailability of drugs subject to first-pass metabolism. Clin Pharmacol Ther 24: 5–10

  16. 16.

    Svensson CK, Edwards DJ, Manriello PM, Barde SH, Foster AC, Lane RN, Middleton E, Lalka D (1983) Effect of food on hepatic blood flow: Implication in the “food effect” phenomenon. Clin Pharmacol Ther 34: 316–323

  17. 17.

    Svensson CK, Cumella JC, Tronolone M, Middleton E, Lalka D (1985) Effects of hydralazine, nitroglycerine, and food on estimated hepatic blood blow. Clin Pharmacol Ther 37: 464–468

  18. 18.

    Landon MJ, Kirkely M (1979) Metabolism of diphenylhydantoin (phenytoin) during pregnancy. Br J Obstet Gynecol 86: 125–132

  19. 19.

    Dam M, Christiansen J, Munck O, Mygind KI (1979) Antiepileptic drugs: Metabolism in pregnancy. Clin Pharmacokinet 4: 53–62

  20. 20.

    Gugler R, Krist R, Raczinski H, Höffgen K, Bodem G (1980). Comparative pharmacodynamics and plasma levels of β-adrenoceptor blocking drugs. Br J Clin Pharmacol 10: 337–343

  21. 21.

    Rubin PC, Butters L, McCabe R, Kelman A (1987) The influence of pregnancy on drug action: Concentration effect modelling with propranolol. Clin Sci 73: 47–52

  22. 22.

    Alvan G, von Bahr C, Seideman P, Sjöqvist F (1982) High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet 1: 333

  23. 23.

    McGourty JC, Silar JH, Lennard MS, Tucker GT, Woods HF (1985) Metoprolol metabolism and debrisoquine oxidation polymorphism — population and family studies. Br J Clin Pharmacol 20: 555–566

  24. 24.

    Steiner E, Spina E (1987) Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquine hydroxylators. Clin Pharmacol Ther 42: 278–282

  25. 25.

    Högstedt S, Lindeberg S, Axelsson O, Lindberg BS, Lindmark G, Rane A, Sandström B (1985) A prospective controlled trial of metoprolol-hydralazine treatment in hypertension during pregnancy. Acta Obstet Gynecol Scand 64: 505–510

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lindeberg, S., Holm, B., Lundborg, P. et al. The effect of hydralazine on steady-state plasma concentrations of metoprolol in pregnant hypertensive women. Eur J Clin Pharmacol 35, 131–135 (1988). https://doi.org/10.1007/BF00609241

Download citation

Key words

  • metoprolol
  • hydralazine
  • hypertension
  • pregnancy
  • pharmacokinetics
  • drug interactions